Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Thalidomide as anti-inflammatory therapy for multiple myeloma

Leukemia volume 17, pages 2237–2238 (2003)Cite this article

TO THE EDITOR

We read with great interest the article by Rajkumar et al1 on the effects of thalidomide in early-stage asymptomatic multiple myeloma. The authors propose that thalidomide may act by suppressing an angiogenic switch, thereby preventing progression of disease.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Rajkumar SV, Gertz MA, Lacy MQ, Dispenzieri A, Fonseca R, Geyer SM et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia 2003; 17: 775–779.

    Article  CAS  Google Scholar 

  2. Potter M, Anderson AO, Nordan RP . Inhibition of plasma-cytoma development in BALB/c mice by indomethacin. J Exp Med 1985; 161: 996–1012.

    Article  CAS  Google Scholar 

  3. Potter M, Wax J, Jones GM . Indomethacin is a potent inhibitor of pristane- and plastic disc-induced plasmacytomagenesis in hypersusceptible BALB/c congenic strain. Blood 1997; 90: 260–169.

  4. Zangari M, Saghafifar F, Mehta P, Barlogie B, Fink L, Tricot G . The blood coagulation mechanism in multiple myeloma. Semin Thromb Hemost 2003; 29: 275–281.

    Article  CAS  Google Scholar 

  5. Meierhofer C, Wiedermann CJ . New insights into the pharmacological and toxicological effects of thalidomide. Curr Opin Drug Discovery Dev 2003; 6: 92–99.

    CAS  Google Scholar 

  6. Settles B, Stevenson A, Wilson K, Mack C, Ezell T, Davis MF et al. Down regulation of cell adhesion molecules LFA-l and ICAM-l after in vitro treatment with the anti TNF alpha agent thalidomide. Cell Mol Biol 200l; 47: 1105–1114.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Arkansas for Medical Sciences and CAVHS, Little Rock, AR, USA

    P Mehta

  2. Cleveland Clinic, Cleveland, OH, USA

    M Hussein

Authors
  1. P Mehta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Hussein
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mehta, P., Hussein, M. Thalidomide as anti-inflammatory therapy for multiple myeloma. Leukemia 17, 2237–2238 (2003). https://doi.org/10.1038/sj.leu.2403118

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403118

This article is cited by

Search

Advanced search

Quick links